-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15

Benzinga·09/23/2026 10:31:50
语音播报
Oppenheimer analyst Les Sulewski initiates coverage on Cormedix (NASDAQ:CRMD) with a Outperform rating and announces Price Target of $15.